Skip to main content
IOF International Osteoporosis Foundation
  1. Home
  2. Term View
Join us !

Social menu

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • BlueSky
Donate
Share
  1. Home
  2. Term View
Role of the clinical laboratory in assessment of metabolic musculoskeletal diseases

Role of the clinical laboratory in assessment of metabolic musculoskeletal diseases

Bone turnover markers have been widely utilised in the field of osteoporosis, particularly for the purpose of monitoring treatment adherence. However, a thorough understanding of the use and interpretation of ...

Read more
January 19, 2023
A systematic approach to fracture prevention

Population screening for fracture risk: a logical step in reducing the osteoporotic fracture burden

The International Osteoporosis Foundation (IOF) Epidemiology and Quality of Life Working Group has reviewed the potential role of population screening for high hip fracture risk against well-established criteria.  The multinational ...

Read more
June 28, 2022
CTI-specal issue

Unusual causes of osteoporosis explored in new series of expert reviews

Osteoporosis predominantly affects postmenopausal women and older men. However, although far more rarely, it can also occur in younger individuals affected by certain conditions and disorders. 

Calcified Tissue International and ...

Read more
April 12, 2022
HIPGEN

HIPGEN 4th Annual Meeting: sharing progress status, updates, and future work plan

The HIPGEN study includes a network of 10 partners from eight countries, as well as the International Osteoporosis Foundation (IOF) as a communications partner. It is a Phase III, multicenter ...

Read more
March 23, 2022
Rehabilitation after fracture

New expert review of the global approach to rehabilitation following fragility fracture

Fragility fractures, which affect an estimated one in three women and one in five men over the age of 50 years worldwide, are a major cause of disability and loss ...

Read more
February 02, 2022
SCOPE-2021-resources

European report reveals a massive treatment gap and disparities in osteoporosis care

Osteoporosis is a major health care burden in Europe which results in 4.3 million fragility fractures and health care costs in excess of €56 billion annually.

Presenting impactful data for ...

Read more
February 01, 2022
HipGen

Important milestone for HIPGEN as it reaches enrolment target

In achieving its enrolment target in November 2021, an important milestone has been reached by the Phase III PLX-PAD study. 

HIPGEN - Cell Therapy for Improving Patient Mobility after Hip Fracture ...

Read more
December 27, 2021
Fig3-common-pathways

Are vascular calcification and bone loss linked disorders of aging?

Vascular calcification, low bone mass and fragility fractures are all frequent age-dependent disorders. Recent clinical and experimental data suggest that vascular calcification and bone loss could share pathophysiological mechanisms. 

A ...

Read more
November 15, 2021
HIPGEN-logo

Learn about the HIPGEN Phase III clinical trial at the Virtual WCO-IOF-ESCEO 2021

‘The Hipgen Trial - Cell Therapy for Improving Patient Mobility after Hip Fracture Arthroplasty’, is among the many topical symposia scheduled at the upcoming virtual World Congress on ...

Read more
August 23, 2021
OP management in chronic CKD stages 4-5D

New guidance on how to diagnosis and manage osteoporosis in chronic kidney disease

Patients with advanced chronic kidney disease (CKD) typically suffer from impaired bone quality and quantity, with a non-vertebral fracture risk which is 4-to 6-fold higher than the fracture risk of ...

Read more
July 15, 2021
HR-pQCT paper

State of the art and future directions in the clinical application of HR-pQCT in adults

Leer esta noticia en español 

A new international guidance on the clinical application of high-resolution peripheral computed tomography (HR-pQCT) offers an important overview of current clinical applications in adults and ...

Read more
June 17, 2021
OP-management-hstc-recipients-executive-summary

How to manage osteoporosis in hematologic stem cell transplant recipients

Impaired bone health is among the most significant long-term consequences of hematopoietic stem cell transplantation (HSCT), a common therapy for patients with malignant and non-malignant haematological diseases. 

To address this ...

Read more
May 03, 2021

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Next page Next ›
  • Last page Last »